Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Age ≥ 18 years old, regardless of gender; Type 2 diabetes; Having a complete medical history and clinical data; If the patients with type 2 diabetes combined with CKD underwent renal biopsy, the pathological diagnosis should be clear; Patients voluntarily signs an informed consent form.

Locations
Other Locations
China
Chinese PLA General Hospital
RECRUITING
Beijing
Contact Information
Primary
Zheyi Dong, MD
shengdai26@163.com
+86 010 66935462
Time Frame
Start Date: 2022-08-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 2000
Treatments
Type 2 diabetic nephropathy
The cohort will be divided into 2 or 3 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
Sponsors
Collaborators: Dongzhimen Hospital, Beijing, China-Japan Friendship Hospital, Xuanwu Hospital, Beijing, Beijing Friendship Hospital, Beijing Tongren Hospital, Beijing Municipal Science & Technology Commission, Beijing Hospital
Leads: Chinese PLA General Hospital

This content was sourced from clinicaltrials.gov